ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 662

Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population?

Laura C Coates, Laura J Savage, Anna R. Moverley and Philip S. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Education, patient, Primary care and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: There is a need for screening
questionnaires to identify patients with psoriasis who have undiagnosed
psoriatic arthritis but the optimal method is unknown.  We developed the
CONTEST questionnaires using the most discriminative items from 3 existing
tools: CONTEST consists of 8 yes/no items and CONTESTji the same items with the
addition of a joint manikin. Our aim was to test the new proposed CONTEST
questionnaires alongside the validated PEST questionnaire in a primary care
setting.

Methods: Patients with psoriasis were identified from
5 GP surgeries in Yorkshire and a random sample were invited to participate in
the study.  Patients had to be over 18 years old, have a diagnosis of psoriasis
and no diagnosis of PsA, RA or AS.  Consenting patients were asked to complete
the PEST and CONTEST questions and were then assessed by a dermatologist and
rheumatologist.  Diagnosis of PsA was made by the assessing rheumatologist as
lab and radiographic data were unavailable to assess the CASPAR criteria.  Receiver
operator characteristic (ROC) curve analysis was used to assess the PEST and
CONTEST questionnaires using physician diagnosis as the gold standard.
Sensitivity and specificity of potential cut points were examined.

Results: A total of 932 packs were sent out to
recruit 191 (20.5%) participants attending for assessment.  Of these, 169
(88.5%) had current or previous psoriasis.  Using physician diagnosis 17 (10.1%)
were found to have previously undiagnosed PsA, 90 (53.3%) were found to have
another musculoskeletal complaint and 62 (36.7%) had no musculoskeletal
problems. 

Using ROC curve analysis, all of the questionnaires showed a
significant ability to identify PsA.  The area under the curve (AUC) for the
CONTEST and CONTESTjt questionnaires was slightly higher than that of PEST (see
table 1) but there was no significant difference between any of the
questionnaires. Examining the sensitivities and specifities for the different
cut points, suggested that a PEST score of ≥2 would perform better in
this dataset, and optimal scores for CONTEST and CONTESTjt seemed to be 3 and 4
respectively.

Conclusion: The accuracy of the PEST and CONTEST
questionnaires to identify PsA appeared similar with slightly higher AUC for
the CONTEST questionnaires.  Optimal cut points in this study appeared lower
than in previous studies (PEST≥2, CONTEST≥3, CONTESTjt≥4).

 

Test

Score

AUC

Sensitivity

Specificity

PEST

2

0.652

0.824

0.449

 

3

0.652

0.529

0.660

 

4

0.652

0.235

0.816

CONTEST

2

0.694

0.882

0.388

 

3

0.694

0.765

0.565

 

4

0.694

0.529

0.680

 

5

0.694

0.353

0.816

CONTESTjt

2

0.704

0.941

0.337

 

3

0.704

0.765

0.531

 

4

0.704

0.706

0.633

 

5

0.704

0.412

0.735

 

6

0.704

0.353

0.844


Disclosure: L. C. Coates, Janssen Pharmaceutica Product, L.P., 2,Janssen Pharmaceutica Product, L.P., 8; L. J. Savage, Janssen Pharmaceutica Product, L.P., 8; A. R. Moverley, None; P. S. Helliwell, Janssen Pharmaceutica Product, L.P., 8,Pfizer Inc, 5.

To cite this abstract in AMA style:

Coates LC, Savage LJ, Moverley AR, Helliwell PS. Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/can-the-new-contest-questionnaire-identify-psoriatic-arthritis-in-a-primary-care-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-the-new-contest-questionnaire-identify-psoriatic-arthritis-in-a-primary-care-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology